• English
  • Korean
  • Chinese
市場調査レポート - 208490

米国のバイオシミラーおよび後続生物製剤市場(2011〜2020年):問題、展望、および予測

US Biosimilar & Follow-On Biologics Market Report (2011-2020): Problems, Prospects & Projections

発行 IMARC Group
出版日 ページ情報 英文
価格
米国のバイオシミラーおよび後続生物製剤市場(2011〜2020年):問題、展望、および予測 US Biosimilar & Follow-On Biologics Market Report (2011-2020): Problems, Prospects & Projections
出版日: 2011年07月30日 ページ情報: 英文
概要

2010年に5,700万米ドルの売上を上げながらも、バイオシミラーは多くのアナリストが期待している10億ドルという売上には程遠い状況にあります。しかし、18の生物医薬品分子が2011〜2020年にバイオシミラーとの競合に直面することが予測されており、米国のバイオシミラー市場は2020年までに114億米ドルに達するとみられています。

当レポートは、米国のバイオシミラー市場を統計的に分析し、市場の現状と実績、今後の売上予測、分子別動向などをまとめ、概略下記の構成でお届けいたします。

第1章 市場の定義と調査方法

第2章 エグゼクティブ・サマリー

第3章 米国におけるバイオシミラー法規制

  • Biologics Price Competition and Innovation Act:概要
  • 未対応のバイオシミラーに関する課題
  • 生物製剤メーカーのビジネス戦略に影響を及ぼす主な課題
    • 互換性と代用性
    • データ独占性
    • 特許訴訟

第4章 米国のバイオシミラー市場環境

第5章 米国のバイオシミラー市場:現状

  • 成長ホルモンバイオシミラーの実績はこれまで散々たる状況
  • Omnitropeの処方パターン
  • 小児科が成長ホルモンの主な顧客基盤
  • Omnitropeは不便なデリバリー装置とともに上市された
  • 市販後の安全データの良好な結果の蓄積によって摂取は増える見込み

第6章 米国のバイオシミラー市場:価格、販売量、売上減少の結果

  • Omnitropeは他のバイオシミラーの実績を測るベンチマークとはならない
  • 欧州のESAおよびGCSF摂取量が米国の良好な見通しを提供
  • 様々な生物製剤クラスにおけるバイオシミラー販売量
  • 様々な生物製剤クラスにおけるバイオシミラーの値下げ
  • 様々な生物製剤クラスにおけるバイオシミラーの売上減少

第7章 米国のバイオシミラー市場:現在の動向と薬剤別予測

  • 成長ホルモン
  • 赤血球生成刺激剤
  • 顆粒球コロニー刺激因子
  • インスリン
  • インターフェロン
  • 癌モノクローナル抗体
  • TNFα

第8章 米国のバイオシミラー市場:適応別現在の動向と予測

  • 免疫学と炎症
  • 糖尿病
  • 血液疾患
  • 発育不全

第9章 競合環境

  • ブランド製品製造業者
  • バイオシミラー製品製造業者
  • 企業プロファイル
    • Teva
    • Sandoz
    • Hospira
    • Stada
    • Dr Reddy's

図表

目次

Abstract

image1

With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint. IMARC Group, one of the world' s leading research and advisory firms, in its new report “US Biosimilar & Follow-On Biologics Market Report (2011-2020): Problems, Prospects & Projections” finds that with eighteen biopharmaceutical molecules expected to face biosimilar competition during 2011 and 2020, the market for biosimilars in the US is expected to reach values worth US$ 11.4 Billion by 2020.

Findings from the report suggest that the historical performance of Omnitrope cannot be taken as a benchmark to gauge the potential of pipeline biosimilars as market acceptance for each biosimilar class is expected to significantly vary from one another. The report expects competition between branded biological drugs and their biosimilar counterparts to represent more that of a brand-brand competition than a brand-generic competition. The high costs involved in the development and launch of biosimilars is expected to limit the number of players in this market and expected to create a significantly lower price and volume erosion compared to that of small molecule generics.

IMARC' s new report entitled “US Biosimilar & Follow-On Biologics Market Report (2011-2020): Problems, Prospects & Projections” provides an analytical and statistical insight into the US biosimilar market. The study that has been undertaken using both desk-based as well as qualitative primary research has analyzed six aspects of the US biosimilar market

Key Aspects Analyzed:

Understanding the Current Legislations on Biosimilars:

  • An insight into the Biologics Price Competition and Innovation Act
  • An insight on the key biosimilar issues that still remain unaddressed
  • Interchangeability and Substitutability
  • Data Exclusivity
  • Provisions for patent litigation

Evaluating the Current Market Landscape for Biosimilars:

  • Identification of current marketed biosimilars and their historical performance
  • Identifying the reasons for the slow uptake of current marketed biosimilars
  • Analyzing historical data to formulate conclusions on the future growth and trends of biosimilars

Evaluating the Extent of Biosimilar Price, Sales and Volume Erosion:

  • Analyzing historical time series data on price, volume and sales erosion in the US & Europe
  • Analyzing previous models and assumptions on biosimilar price and volume erosion
  • Evaluating and comparing biosimilar price and volume erosion with that of small molecule generics
  • Evaluating and comparing biosimilar price, volume and sales erosion across various biological classes

Evaluating the Sales and Volume Erosion of Biosimilars across Various Molecules:

Molecules Covered: Somatropin, Epoitin Alfa, Darbepoetin Alfa, Filgrastim, Pegfilgrastim, Insulin Lispro, Insulin Glargin, Insulin Detemir, Interferon Beta-1A, Interferon Beta-1B, Bevacizumab, Trastuzumab, Rituximab, Cetuximab, Ethanercept, Infliximab and Adalimumab

Focus of the Analysis for Each Molecule:

  • Historical Background and Overview
  • Historical Brand Sales
  • Brand and Biosimilar Sales Forecast

Evaluating the Sales of Biosimilars across Various Indications:

Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency

Focus of the Analysis for Each Indication:

  • Historical Brand Sales
  • Brand & Biosimilar Sales Forecast
  • Biosimilar Sales Forecast by Molecule

Evaluating the Biosimilar Competitive Landscape:

  • Identifying branded biological manufacturers that expect the highest amount of biosimilar erosion
  • Identifying biosimilar manufacturers and their current partnerships and pipelines

About IMARC Group

For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

Table of Contents

1. Market Definitions & Research Methodology

2. Executive Summary

3. Biosimilar Legislation in the US

  • 3.1. The Biologics Price Competition and Innovation Act: An Insight
  • 3.2. Biosimlar Issues that Still Remain Unaddressed
  • 3.3. Major Issues Impacting the Business Strategies of Biological Companies
    • 3.3.1. Interchangeability & Substitutability
    • 3.3.2. Data Exclusivity
    • 3.3.3. Patent Litigation

4. The US Biosimilar Market Landscape

5. US Biosimilar Market: Current Experience

  • 5.1. The Performance of Growth Hormone Biosimilars Has Been Dismal So Far
  • 5.2. Prescribing Patterns for Omnitrope
  • 5.3. Pediatrics Represent the Prime Customer Base of Growth Hormones
  • 5.4. Omnitrope was Launched with an Inconvenient Delivery Device
  • 5.5. Uptake is Likely to Increase with an Accumulation of a Positive Post-Market Safety Data

6. US Biosimlar Market: How Much Price, Volume & Sales Erosion will Result

  • 6.1. Omnitrope Cannot be Taken as a Benchmark to Gauge the Performance of Other Biosimilars
  • 6.2. The European Uptake of ESA & GCSF Give Us a Very Positive Outlook for the US
  • 6.3. Current & Future Biosimilar Volume Erosion Across Various Biological Classes
  • 6.4. Current & Future Biosimilar Price Erosion Across Various Biological Classes
  • 6.5. Current & Future Biosimilar Sales Erosion Across Various Biological Classes

7. US Biosimilar Market: Current Trends & Forecast by Drug

  • 7.1. Growth Hormones
    • 7.1.1. Somatropin (Genotropin/Humatrope/Other HGH)
      • 7.1.1.1. Drug Overview
      • 7.1.1.2. Current Brand & Biosimilar Sales
      • 7.1.1.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.2. Erythropoiesis-Stimulating Agents
    • 7.2.1. Epoetin Alfa (Epogen/Eprex)
      • 7.2.1.1. Drug Overview
      • 7.2.1.2. Historical Brand Sales
      • 7.2.1.3. Brand & Biosimilar Forecasts (2011-2020)
    • 7.2.2. Darbepoetin Alfa (Aranesp)
      • 7.2.2.1. Drug Overview
      • 7.2.2.2. Historical Brand Sales
      • 7.2.2.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.3. Granulocyte Colony Stimulating Factor
    • 7.3.1. Filgrastim (Neupogen)
      • 7.3.1.1. Drug Overview
      • 7.3.1.2. Historical Brand Sales
      • 7.3.1.3. Brand & Biosimilar Forecasts (2011-2020)
    • 7.3.2. Pegfilgrastim (Neulasta)
      • 7.3.2.1. Drug Overview
      • 7.3.2.2. Historical Brand Sales
      • 7.3.2.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.4. Insulin
    • 7.4.1. Insulin Lispro (Humalog)
      • 7.4.1.1. Drug Overview
      • 7.4.1.2. Historical Brand Sales
      • 7.4.1.3. Brand & Biosimilar Forecasts (2011-2020)
    • 7.4.2. Insulin Glargine (Lantus)
      • 7.4.2.1. Drug Overview
      • 7.4.2.2. Historical Brand Sales
      • 7.4.2.3. Brand & Biosimilar Forecasts (2011-2020)
    • 7.4.3. Insulin Detemir (Levemir)
      • 7.4.3.1. Drug Overview
      • 7.4.3.2. Historical Brand Sales
      • 7.4.3.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.5. Interferons
    • 7.5.1. Interferon Beta-1A (Avonex)
      • 7.5.1.1. Drug Overview
      • 7.5.1.2. Historical Brand Sales
      • 7.5.1.3. Brand & Biosimilar Forecasts (2011-2020)
    • 7.5.2. Interferon Beta-1A (Rebif)
      • 7.5.2.1. Drug Overview
      • 7.5.2.2. Historical Biosimilar Sales
      • 7.5.2.3. Brand & Biosimilar Forecasts (2011-2020)
    • 7.5.3. Interferon Beta-1B (Betaferon/Betaseron)
      • 7.5.3.1. Drug Overview
      • 7.5.3.2. Historical Biosimilar Sales
      • 7.5.3.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.6. Oncology Monoclonal Antibodies
    • 7.6.1. Bevacizumab (Avastin)
      • 7.6.1.1. Drug Overview
      • 7.6.1.2. Historical Brand Sales
      • 7.6.1.3. Brand & Biosimilar Forecasts (2011-2020)
    • 7.6.2. Trastuzumab (Herceptin)
      • 7.6.2.1. Drug Overview
      • 7.6.2.2. Historical Biosimilar Sales
      • 7.6.2.3. Brand & Biosimilar Forecasts (2011-2020)
    • 7.6.3. Rituximab (Rituxan)
      • 7.6.3.1. Drug Overview
      • 7.6.3.2. Historical Biosimilar Sales
      • 7.6.3.3. Brand & Biosimilar Forecasts (2011-2020)
    • 7.6.4. Cetuximab (Erbitux)
      • 7.6.4.1. Drug Overview
      • 7.6.4.2. Historical Brand Sales
      • 7.6.4.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.7. TNF Alpha
    • 7.7.1. Etanercept (Enbrel)
      • 7.7.1.1. Drug Overview
      • 7.7.1.2. Historical Brand Sales
      • 7.7.1.3. Brand & Biosimilar Forecasts (2011-2020)
    • 7.7.2. Infliximab (Remicade)
      • 7.7.2.1. Drug Overview
      • 7.7.2.2. Historical Brand Sales
      • 7.7.2.3. Brand & Biosimilar Forecasts (2011-2020)
    • 7.7.3. Adalimumab (Humira)
      • 7.7.3.1. Drug Overview
      • 7.7.3.2. Historical Brand Sales
      • 7.7.3.3. Brand & Biosimilar Forecasts (2011-2020)

8. US Biosimilar Market: Current Trends & Forecast by Indication

  • 8.1. Immunology & Inflammation
    • 8.1.1. Current Trends & Forecast
    • 8.1.2. Biosimilar Sales Breakup by Molecule
  • 8.2. Diabetes
    • 8.2.1. Current Trends & Forecast
    • 8.2.2. Biosimilar Sales Breakup by Molecule
  • 8.3. Oncology
    • 8.3.1. Current Trends & Forecast
    • 8.3.2. Biosimilar Sales Breakup by Molecule
  • 8.4. Blood Disorder
    • 8.4.1. Current Trends & Forecast
    • 8.4.2. Biosimilar Sales Breakup by Molecule
  • 8.5. Growth Deficiency
    • 8.5.1. Current Trends & Forecast
    • 8.5.2. Biosimilar Sales Breakup by Molecule

9. Competitive Landscape

  • 9.1. Branded Manufacturers: Companies Facing the Highest Amount of Biosimilar Erosion
  • 9.2. Biosimilar Manufacturers: Companies Gaining the Most From Biosimilar Launches
  • 9.3. Key Company Profiles
    • 9.3.1. Teva
    • 9.3.2. Sandoz
    • 9.3.3. Hospira
    • 9.3.4. Stada
    • 9.3.5. Dr Reddy' s

LIST OF FIGURES

  • Figure 1 - 1: Model Used to Forecast Brand and Biosimilar Sales
  • Figure 4 - 1: US: Biosimilar Market (in Million US$), 2007-2010
  • Figure 4 - 2: US: Biosimilar Market Forecast (in Million US$), 2011-2020
  • Figure 5 - 1: US: Human Growth Hormone Market: Share of Different Brands & Biosimilars (in %), 2007-2010
  • Figure 5 - 2: US: Endocrinologist Prescribing Patterns for Omnitrope (in %), 2008
  • Figure 5 - 3: US: Share of Omnitrope in New & Switch Human Growth Hormone Patients, (in %), 2008
  • Figure 5 - 4: US: Human Growth Hormone Market: Brand & Biosimilar Patient Share (in %), 2007-2020
  • Figure 6 - 1: US, Germany, France, Italy, Spain & UK: Somatropin Biosimilars: Patient Share (in %), 2007-2010
  • Figure 6 - 2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010
  • Figure 6 - 3: US: Percentage of Physicians Expected to Prescribe ESA Biosimilars After They Have Been Launched, (in %), 2010
  • Figure 6 - 4: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2010
  • Figure 6 - 5: Average Generic Volume Erosion of Molecules Based-on Complex Drug Characteristics, (in %)
  • Figure 6 - 6: Average Generic Volume Erosion Across Various Countries From Time Since First Generic Entry, (in %)
  • Figure 6 - 7: Average Generic Price Erosion of Molecules Based Upon Complex Drug Characteristics, (in %)
  • Figure 6 - 8: Average Generic Price Erosion Across Various Countries From Time Since First Generic Entry
  • Figure 6 - 9: Average Brand Price Erosion Across Various Countries From Time Since First Generic Entry
  • Figure 7 - 1: US: Biosimilar Market: Share by Molecule (in %), 2011-2020
  • Figure 7 - 2: US: Somatropin Market: Brand & Biosimilar Sales Share (in %), 2007-2010
  • Figure 7 - 3: US: Somatropin Market: Share of Marketed Brands & Biosimilars (in %), 2007-2010
  • Figure 7 - 4: US: Somatropin Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 5: US: Epoetin Alfa: Share of Marketed Brands (in %), 2007-2010
  • Figure 7 - 6: US: Epoetin Alfa Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 7 : US: Darbepoetin Alfa Market Forecast: Share of Brand & Biosimilar Sales Forecast (in %), 2011-2020
  • Figure 7 - 8 : US: Filgrastim Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 9 : US: Pegfilgrastim Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 10 : US: Insulin Lispro Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Figure 7 - 11 : US: Insulin Glargine Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 12 : US: Insulin Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 13 : US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 14 : US: Interferon Beta-1A (Rebif) Market: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 15 : US: Interferon Beta-1B Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 16 : US: Bevacizumab Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 17 : US: Trastuzumab Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 18 : US: Rituximab Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 19 : US: Cetuximab Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 20 : US: Ethanercept Market: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7 - 21 : US: Infliximab Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 8 - 1: US: Biosimilar Market Forecast: Share by Indication (in %), 2011-2020
  • Figure 8 - 2: US: Immunology & Inflammation Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
  • Figure 8 - 3: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
  • Figure 8 - 4: US: Diabetes Market forecast: Brand & Biosimilar Share (in %), 2011-2020
  • Figure 8 - 5: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
  • Figure 8 - 6: US: Oncology Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
  • Figure 8 - 7: US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
  • Figure 8 - 8: US: Blood Disorder Market Forecast: Brand & Biosimilar Sales (in %), 2011-2020
  • Figure 8 - 9: US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
  • Figure 8 - 10: US: Growth Deficiency Market: Brand & Biosimilar Share (in %), 2007-2010
  • Figure 8 - 11: US: Growth Deficiency Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
  • Figure 9 - 1: US: Innovator Companies Facing the Highest Amount of Biosimilar Sales Erosion (in %), 2010,2013,2016,2020
  • Figure 9 - 2: Key Biosimilar Partnerships

LIST OF TABLES

  • Table 1 - 1: US Biosimilar/Follow-On Biologics Market: Market Definition & Overview
  • Table 3 - 1: US - Overview of Biosimilar Legislations
  • Table 3 - 2: Comparison of Patent Protection and Data Exclusivity
  • Table 4 - 1: US: Patent Expiries and Biosimilar Launch
  • Table 6 - 1: Biosimilar Vulnerability of Various Biopharmaceutical Classes
  • Table 6 - 2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010
  • Table 6 - 3: US: Various Studies & Assumptions for Biosimilar Volume Erosion
  • Table 6 - 4: US, Germany and UK: Biosimilar Volume Penetration After 5 years from Launch (in %)
  • Table 6 - 5: Various Studies & Assumptions for Biosimilar Price Erosion
  • Table 6 - 6: US, Germany and UK: Biosimilar Sales Penetration after 5 years from Launch, (in %)
  • Table 7 - 1: US: Biosimilar Sales by Molecule (in Million US$), 2007-2010
  • Table 7 - 2: US: Biosimilar Sales by Molecule (in Million US$), 2011-2020
  • Table 7 - 3: US: Somatropin: Brand & Biosimilar Market Overview
  • Table 7 - 4: US: Somatropin Market: Brand & Biosimilar Sales/Patient Share, 2007-2010
  • Table 7 - 5: US: Somatropin Market: Sales of Marketed Brands & Biosimilars (in Million US$), 2007-2010
  • Table 7 - 6: US: Somatropin Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 7: US: Epoetin alfa: Brand & Biosimilar Market Overview
  • Table 7 - 8: US: Epoetin Alfa: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 9: US: Epoetin Alfa: Sales of Marketed Brands (in Million US$), 2007-2010
  • Table 7 - 10: US: Epoetin Alfa Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 11: US: Darbepoetin Alpha: Brand & Biosimilar Market Overview
  • Table 7 - 12: US: Darbepoetin Alpha Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 13: US: Darbepoetin Alfa Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 14: US: Filgrastim: Brand & Biosimilar Market Overview
  • Table 7 - 15: US: Filgrastim Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 16: US: Filgrastim Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 17: US: Pegfilgrastim: Brand & Biosimilar Market Overview
  • Table 7 - 18: US: Pegfilgrastim Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 19: US: Pegfilgrastim Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 20: US: Insulin Lispro: Brand & Biosimilar Market Overview
  • Table 7 - 21: US: Insulin Lispro Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 22: US: Insulin Lispro Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 23: US: Insulin Glargine: Brand & Biosimilar Market Overview
  • Table 7 - 24: US: Insulin Glargine Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 25: US: Insulin Glargine Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 26: US: Insulin Detemir: Brand & Biosimilar Market Overview
  • Table 7 - 27: US: Insulin Detemir Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 28: US: Insulin Detemir Market: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 29: US: Interferon Beta-1A (Avonex) Market: Brand & Biosimilar Market Overview
  • Table 7 - 30: US: Interferon Beta-1A (Avonex) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 31: US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 32: US: Interferon Beta-1A (Rebif): Brand & Biosimilar Market Overview
  • Table 7 - 33: US: Interferon Beta-1A (Rebif) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 34: US: Interferon Beta-1A (Rebif) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 35: US: Interferon Beta-1B: Brand & Biosimilar Market Overview
  • Table 7 - 36: US: Interferon Beta-1B Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 37: US: Interferon Beta-1B Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 38: US: Bevacizumab: Brand & Biosimilar Market Overview
  • Table 7 - 39: US: Bevacizumab Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 40: US: Bevacizumab Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 41: US: Trastuzumab: Brand & Biosimilar Market Overview
  • Table 7 - 42: US: Trastuzumab Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 43: US: Trastuzumab Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 44: US: Rituximab: Brand & Biosimilar Market Overview
  • Table 7 - 45: US: Rituximab Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 46: US: Rituximab Market: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 47: US: Cetuximab: Brand & Biosimilar Market Overview
  • Table 7 - 48: US: Cetuximab Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 49: US: Cetuximab Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 50: US: Etanercept: Brand & Biosimilar Market Overview
  • Table 7 - 51: US: Etanercept Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 52: US: Ethanercept Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 53: US: Infliximab: Brand & Biosimilar Market Overview
  • Table 7 - 54: US: Infliximab Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 55: US: Infliximab Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7 - 56: US: Adalimumab: Brand & Biosimilar Market Overview
  • Table 7 - 57: US: Adalimumab Market: Brand Sales (in Millions US$), 2007-2010
  • Table 7 - 58: US: Adalimumab Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 8 - 1: US: Biosimilars Market: Sales by Indication (in Million US$), 2007-2010
  • Table 8 - 2: US: Biosimilar Market Forecast: Sales by Indication (in Million US$), 2011-2020
  • Table 8 - 3: US: Immunology & Inflammation Market: Brand Sales (in Million US$), 2007-2010
  • Table 8 - 4: US: Immunology & Inflammation Market Forecast: Branded & Biosimilar Sales (in Million US$), 2011-2020
  • Table 8 - 5: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
  • Table 8 - 6: US: Diabetes Market: Brand Sales (in Million US$), 2007-2010
  • Table 8 - 7: US: Diabetes Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
  • Table 8 - 8: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
  • Table 8 - 9: US: Oncology Market: Brand Sales (in Million US$), 2007-2010
  • Table 8 - 10 : US: Oncology Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
  • Table 8 - 11 US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
  • Table 8 - 12 : US: Blood Disorder Market: Brand Sales (in Million US$), 2007-2010
  • Table 8 - 13 : US: Blood Disorder Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
  • Table 8 - 14 : US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
  • Table 8 - 15 : US: Growth Deficiency Market: Brand & Biosimilar Sales (in Million US$), 2007-2010
  • Table 8 - 16 : US: Growth Deficiency Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
  • Table 9 - 1: US: Innovator Companies Facing the Highest Amount of Biosimilar Sales Erosion (in Million US$), 2010, 2013, 2016 & 2020
  • Table 9 - 3: Selected Public Companies with Biosimilar Activities
  • Table 9 - 4: Global: Biosimilar Product Development Status
Back to Top